Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Company Overview - Adverum Biotechnologies, Inc. is a clinical-stage company focused on gene therapy for prevalent ocular diseases aiming to establish a new standard of care [2] - The company is developing a one-time, intravitreal injection therapy, ixoberogene soroparvovec (Ixo-vec), for patients with neovascular or wet age-related macular degeneration [2] - Adverum's goal is to create durable therapies that eliminate the need for frequent ocular injections, thereby transforming the treatment landscape for debilitating ocular diseases [2] Upcoming Events - Adverum will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET [1] - The company will also participate in Chardan's 8th Annual Genetic Medicines Conference on October 1st at 8:00 a.m. ET [1] - Additionally, Adverum will be featured in the UBS Virtual Ophthalmology Day on October 2nd at 10:30 a.m. ET [1] Access to Information - On-demand webcasts of the presentations will be available under the Events and Presentations section on Adverum's website [1] - Each webcast will be accessible for at least 30 days following the events [1]